GET DAILY SIGNALSInsulet (PODD) Reports Q3 2026 Revenue Up +19.2% and Strong EPS Beat
Key Takeaways
- Insulet reported third-quarter 2026 revenue of $842 million, up 19.2% year over year, edging above the roughly $833 million consensus estimate.
- Adjusted earnings per share came in at $1.99, well ahead of the $1.59 analyst consensus and up 27.5% from the prior-year period.
- The company posted record gross margin and expanded operating margin, reflecting manufacturing scale and productivity gains.
- Management narrowed its full-year 2026 revenue outlook to the top end of its prior range, while signaling a more conservative stance on 2027.
- The board approved a $1 billion increase to the share repurchase authorization, with about $400 million expected to be deployed in Q4.
Earnings Context and Why It Matters
Insulet, the global leader in tubeless insulin pump technology behind the Omnipod brand, delivered its Q3 2026 results against a backdrop of rising competitive intensity in the automated insulin delivery (AID) market. The report matters because it tests whether the company can sustain its top-tier growth while new rival products enter the category and type 2 diabetes retention remains a focus. Following a sharp selloff after its Q2 report, when management cut full-year guidance on softer U.S. type 2 trends, investors were watching closely for evidence that corrective actions were taking hold. Strong international momentum and margin expansion offered reassurance, while early 2027 commentary introduced fresh caution about the pace of future growth. I also checked this using Tickeron’s AI Screener to see how PODD compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Insulet posted revenue of $842 million, an increase of 19.2% year over year, or 19.6% in constant currency. The figure modestly exceeded the consensus estimate of about $833 million. Adjusted earnings per share reached $1.99, comfortably beating the $1.59 consensus, while GAAP diluted earnings per share came in at $2.03, up from $1.24 a year earlier. Net income rose to $141.1 million from $87.6 million in the prior-year period.
Total Omnipod revenue was $836.6 million, up 19.7%. U.S. Omnipod revenue grew 14.7% to $570.4 million, while International Omnipod revenue climbed 31.7% to $266.2 million, up 33.0% in constant currency. The smaller Drug Delivery segment declined 22.7% to $5.5 million. Operating income reached $189.8 million, or 22.5% of revenue, up 590 basis points year over year, helped by record gross margin and ongoing productivity improvements. From what I see, the margin expansion highlights the benefits of scale in a competitive space.
Market Reaction and Investor Sentiment
Insulet shares responded cautiously to the report, with initial gains tempered by management's preliminary 2027 commentary. The headline beat on both revenue and earnings supported sentiment, as did the narrowed full-year 2026 guidance and the expanded buyback authorization. However, management indicated that 2027 total company growth is expected to come in modestly below its prior mid-teens framework, with U.S. growth toward the lower end of the 9% to 14% range and a meaningful slowdown internationally. That more conservative posture, tied to the timing of new product launches and a much larger revenue base, weighed on investor enthusiasm and reinforced the market's sensitivity to forward guidance rather than backward-looking beats.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on how Insulet balances near-term execution with its longer-term innovation pipeline. The company has submitted the second and final 510(k) application for Omnipod 6 and continues to target a 2027 launch, positioning the next-generation platform as a key catalyst. Management framed the 2027 slowdown as a function of product-launch timing and scale, but the market will want clearer evidence that growth can re-accelerate once Omnipod 6 reaches full commercialization.
Several factors warrant monitoring in the coming quarters. First, type 2 diabetes retention remains central: management reported modest improvement in Q3 from its corrective action plan, including salesforce expansion, revised compensation, and onboarding enhancements. Sustained retention gains would support the U.S. growth outlook. Second, the ramp of Omnipod Discover, now adopted by more than 35,000 users, could strengthen engagement and loyalty. Third, investors will watch the remaining U.S. pharmacy benefit manager (PBM) contract renewals for 2027, which could shape broad access across the pharmacy channel. I’m watching this closely as the competitive landscape evolves.
Finally, cost trends and capital allocation will stay in focus. The record gross margin and expanded operating margin demonstrate the benefits of manufacturing scale, while the $1 billion buyback increase and planned $400 million Q4 repurchase signal management's confidence in cash generation. Balancing these reinvestments against a more dynamic competitive environment will be a defining theme heading into 2027. One thing that stands out is how the buyback signals confidence amid the guidance shift.
Exploring AI Tools for Earnings Analysis
In my analysis of recent movers like PODD, I often turn to Tickeron’s AI Screener to quickly filter for comparable setups in the medical device space. It helps surface ideas based on fundamentals, patterns, and signals without manual effort, which keeps my research efficient when reviewing quarterly results and peer performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PODD in upward trend: price rose above 50-day moving average on October 16, 2026
PODD moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on PODD as a result. In 70 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for PODD just turned positive on October 06, 2026. Looking at past instances where PODD's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
The 10-day moving average for PODD crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where PODD advanced for three days, in 207 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 104 of 174 cases where PODD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
PODD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. PODD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.552) is normal, around the industry mean (4.170). P/E Ratio (28.892) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (1.047) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.294) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of insulin infusion systems
Industry MedicalNursingServices
Advertisement